Pregled bibliografske jedinice broj: 1059408
Updates from the Global Meningococcal Initiative in Eastern Europe
Updates from the Global Meningococcal Initiative in Eastern Europe // Journal of Infection, 79 (2019), 6; 528-541 doi:10.1016/j.jinf.2019.10.018 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1059408 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Updates from the Global Meningococcal Initiative
in Eastern Europe
(Prevention and control of meningococcal
disease: Updates from the Global Meningococcal
Initiative in Eastern Europe)
Autori
Bai, Xilian ; Borrow, Ray ; Bukovski, Suzana ; Caugant, Dominique A. ; Culic, Davor ; Delic, Snezana ; Dinleyici, Ener Cagri ; Eloshvili, Medeia ; Erdősi, Tímea ; Galajeva, Jelena ; Křížová, Pavla ; Lucidarme, Jay ; Mironov, Konstantin ; Nurmatov, Zuridin ; Pana, Marina ; Rahimov, Erkin ; Savrasova, Larisa ; Skoczyńska, Anna ; Smith, Vinny ; Taha, Muhamed-Kheir ; Titov, Leonid ; Vázquez, Julio ; Yeraliyeva, Lyazzat
Izvornik
Journal of Infection (0163-4453) 79
(2019), 6;
528-541
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Antibiotic resistance Bacterial meningitis Conjugate vaccine Easter Europe
(Antibiotic resistanceBacterial meningitis Conjugate vaccine Easter Europe)
Sažetak
The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100, 000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines ; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-riskgroups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.
Izvorni jezik
Engleski
POVEZANOST RADA
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević",
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
Suzana Bukovski
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE